For media inquiries: Julie Rathbun Rathbun Communications julie@rathbuncomm.com 206-769-9219
March 14, 2024
Mozart Therapeutics Presents Non-clinical Data on Lead Program, MTX-101 for Treatment of Autoimmune Diseases, at Society of Toxicology Annual Meeting 2024
November 13, 2023
Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel Bispecific CD8 Treg Modulator for Treatment of Autoimmune Diseases, at American College of Rheumatology Convergence 2023
October 30, 2023
Mozart Therapeutics Expands Executive Leadership Team with Appointments of Dr. Jason Chien, Chief Medical Officer, and Russ Hawkinson, Chief Financial Office
Gerold Nepom, MD, PhD joins Scientific Advisory Board
More Press Releases